Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC
Notified -
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-04-28, 20:23
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-04-10, 19:03
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-03-29, 01:33
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-03-24, 15:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-03-23, 03:39
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-03-21, 08:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-03-11, 14:30
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-03-05, 13:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-03-04, 15:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-03-04, 13:00
